48results about How to "Reduction in severity and frequency" patented technology

The invention relates to a method of treating diverse human disorders that may arise, in part, out of sleep hypoxia and oxygen deprivation occurring in the context of sleep apnea/hypopnea disturbances. The disorders that may be treated by the invention comprise gastroesophageal reflux disease (GERD), asthma-associated gastroesophageal reflux (GER), GER-associated asthma, asthma, cardiomyopathy, cardioarrhythmia, congestive heart failure, sudden infant death syndrome, and diverse neurologic conditions. The mode of treatment uses somatostatin receptor ligands (SstRLs), particularly somatostatin-receptor agonists. The invention concerns the method of treatment utilizing, and compositions comprising SstRLs and somatostatin receptor agonists, including agonists of the somatostatin receptor types 2 and 5, particularly, the type 2A receptor (SsR-2A), including octreotide and lanreotide.

A display substrate includes a substrate, a guard ring and a connecting line. The substrate includes a plurality of active areas, and each of the active areas has a pixel area and a peripheral area. The guard ring is formed on the substrate to enclose each of the active areas, and is formed from substantially the same layer as a pixel electrode that is formed in a unit pixel. The connecting line is formed from a different layer than the guard ring, to electrically connect the guard ring with pads. The connecting line is formed before forming an organic insulating layer, and thus the frequency and/or severity of patterning defects of the connecting line may be reduced or prevented. Accordingly, short circuits between the pads may be prevented, and the corrosion resistance of the display apparatus may be increased.

An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.

Compositions and methods of treating or preventing hot flashes, night sweats, and/or insomnia in a subject that involve scopolamine are disclosed. For example, methods of treating hot flashes, night sweats, and/or insomnia in a subject that involve transdermal delivery of scopolamine are set forth herein.

There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to SEQ ID NO: 4 and which comprises six asparagine residues. Also provided is a functional factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g. haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.

Implementations of the present invention relate to apparatuses, systems, and methods for blocking, attenuating, or filtering neuroactive wavelengths of the visible light spectrum and reducing or preventing the symptoms affiliated with exposure to those wavelengths. Nanoparticles of a predetermined composition, size, and structure are dispersed in a host medium to create an optical notch filter, thereby attenuating only a narrow range of the visible spectrum.

Implementations of the present invention relate to apparatuses, systems, and methods for blocking, attenuating, or filtering neuroactive wavelengths of the visible light spectrum and reducing or preventing the symptoms affiliated with exposure to those wavelengths. Nanoparticles of a predetermined composition, size, and structure are dispersed in a host medium to create an optical notch filter, thereby attenuating only a narrow range of the visible spectrum.

The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a cyclooxygenase-2 inhibitor and an antineoplastic agent.

A method of treating symptoms of benign prostatic hypertrophy and a method of treating lower urinary tract symptoms, are disclosed. The method includes administering to a mammal about 1 to about 20 milligrams of an agent that inhibits cyclic guanosine 3,5-monophosphate specific phosphodiesterase type 5.

The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and rumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.

Topical formulations comprising inhibitors of dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and/or uridine phosphorylase (UP) enzyme inhibitors are provided for the treatment of hand-foot syndrome (HFS) in cancer patients undergoing treatment with 5-FU and 5-FU prodrugs.

The present disclosure provides methods of treating age related disorders through the administration of collagen 7 or the functional fragment or variant thereof

A system for treating and preventing multiple forms of acne includes applying a solution to the skin to assist maintaining the skin's natural acidic mantle of 4.0 to 6.5, preserve moisture transport properties, and maintain specialized lipid content, allowing the skin to function normally, and assisting the skin to heal wounds caused by acne and associated bacterial infections. The method steps include one or more of the following: applying the formulation with surfactants incorporated therein to the skin as a cleanser, rinsing with water; applying the solution, with or without surfactants, and allowing the solution to air dry; repeating the applications and allowing them to air dry throughout the day; and repeating the cleansing and rinsing steps and applying the solution and allowing to air dry before retiring. One or more of the method steps may be repeated on a continual basis, typically daily, for an extended period of time.